Entry Point Capital, LLC Alnylam Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding ALNY
# of Institutions
614Shares Held
108MCall Options Held
2.33MPut Options Held
2.17M-
Capital World Investors Los Angeles, CA15MShares$3.69 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.08 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.35 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.53 Billion0.28% of portfolio
-
Baillie Gifford & CO6.03MShares$1.49 Billion1.16% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $30.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...